Please Wait.....
Report
Recombinant Protein Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)
Market Report I 2023-01-23 I 120 Pages I Mordor Intelligence
The recombinant protein market was valued at approximately USD 1,064 million in 2021 and is estimated to grow with a CAGR of 9.92 % over the forecast period, 2022-2027.
COVID-19 had a significant impact on the growth of the recombinant protein market. With the onset of COVID-19, there had been an increased need for therapeutic and vaccination for its treatment. Many market players and public organizations shifted their focus to research and development activities for the treatment of COVID-19, and recombinant proteins played a vital role in them. For instance, in October 2020, Novavax Inc. received USD 4 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of a COVID-19 vaccine based on its proprietary recombinant protein nanoparticle technology platform. Thus, such developments amid the pandemic had a pronounced impact on the growth of the market.
Factors such as increasing expenditure on research and development; the growing prevalence of chronic diseases; geriatric population; rising inclination towards biologics and biosimilars; and the launch of advanced recombinant products majorly drive the growth of the market.
According to the American Cancer Society's 2022 statistics, in the United States, there will be an estimated 1,918,030 new cancer cases in 2022. Such a high burden of cancer creates the need for advanced therapeutics for the treatment, and since recombinant proteins are largely used in therapeutics and the development of cancer therapies, such an increase in the cancer burden is expected to drive the demand for recombinant proteins, thereby driving the market's growth. Additionally, increasing investments in research and development aimed at the introduction of new recombinant protein therapeutics also contribute to the growth of the market. For instance, in January 2020, Airway Therapeutics Inc. received USD 15.5 million in a Series C financing round to develop the company's AT-100 novel recombinant human protein rhSP-D, an investigational preventive treatment for the serious respiratory disease bronchopulmonary dysplasia (BPD).
Furthermore, in September 2021, Aviva Systems Biology, one of the companies engaged in manufacturing and developing antibodies, immunoassay kits, and recombinant proteins for life science research, launched its new protein-on-demand semi-custom recombinant protein portfolio for life scientists conducting basic research and preclinical studies.
Thus, the recombinant protein market is expected to project significant growth over the forecast period. However, the time-consuming and high cost of production processes and high costs coupled with safety issues may hamper the market's growth over the forecast period.
Recombinant Protein Market Trends
The Antibody Segment is Expected to Grow at the Fast Rate Over the Forecast Period
The recombinant antibody production procedure involves cloning antibody gene libraries into phage vectors and allowing the phages to infect a host cell line. The host cells then produce daughter phages expressing the recombinant antibodies on their surfaces. The genes can be inserted into an expression system, and the antibodies can be produced in large quantities after a process of selection for antibodies with the desired characteristics.
Collaboration among the market players and research institutes is also expected to propel the growth of the market segment. For instance, in June 2020, the Recombinant Antibody Network (RAN), a consortium comprising research groups from UC San Francisco, the University of Chicago, and the University of Toronto, entered into a research collaboration with Celgene, a Bristol Myers Squibb company, to create and develop high-performance recombinant antibodies against diverse targets in human cells.
Companies are also involved in the development of recombinant antibodies for COVID-19 infection. For instance, in February 2021, Sanofi and GSK initiated a new phase 2b study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for phase 3 evaluation of the adjuvanted recombinant protein COVID-19 vaccine candidate. Also, in September 2020, GigaGen Inc., in collaboration with Waisman Biomanufacturing and Goodwin Biotechnology Inc., initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug GIGA-2050 for the treatment of COVID-19.
Hence, the aforementioned factors are expected to drive market growth in this segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period
North America is expected to lead the recombinant protein market, owing to the increasing expenditure on research, coupled with the presence of healthcare infrastructure and several major market players. The chronic diseases that are on the rise across the region are creating a huge demand for recombinant protein therapies, as recombinant proteins are among the proven solutions for treating such diseases. According to GLOBOCAN statistics, in 2020, 195,499 new cancer cases were diagnosed in Mexico. Such a high incidence of cancer creates the need for effective therapeutics and thus propels the growth of the market.
Furthermore, the presence of key players in the market and the launch of products are also propelling the growth of the market. For instance, in June 2020, Sandoz Canada Inc., a division of Novartis AG, received Health Canada approval for its Ziextenzo, a long-acting recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) indicated to decrease the incidence of infection in patients with non-myeloid malignancies. Additionally, increasing investment in recombinant DNA and protein technologies to address the situation also boosts the growth of the market. For instance, in April 2020, Sanofi and GSK collaborated to develop vaccines based on Sanofi's recombinant forms of S-protein COVID-19 antigen and GSK's adjuvant technology.
Thus, owing to the abovementioned factors, the market in the North American region is expected to project growth over the forecast period.
Recombinant Protein Market Competitor Analysis
The recombinant protein market is moderately competitive and consists of several major players, including Eli Lilly and Company, Merck KGaA, and Novo Nordisk AS. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, that help them strengthen their market positions.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Expenditure on Research and Development
4.2.2 Growing Burden of Chronic Diseases
4.2.3 Rising Inclination toward Biologics and Biosimilars
4.2.4 Technological Advancements in Recombinant Products
4.3 Market Restraints
4.3.1 Expensive and Time-consuming Production Process
4.3.2 Safety Issues
4.4 Porters' Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product
5.1.1 Hormone
5.1.2 Growth Factor
5.1.3 Antibody
5.1.4 Enzyme
5.1.5 Other Types of Products
5.2 By Application
5.2.1 Research Application
5.2.2 Therapeutic Use
5.2.3 Biotechnology Industry
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abcam PLC
6.1.2 Amgen Inc.
6.1.3 Bio-Rad Laboratories Inc.
6.1.4 Eli Lilly and Company
6.1.5 Merck KGaA
6.1.6 Novo Nordisk AS
6.1.7 Sanofi SA
6.1.8 Thermo Fisher Scientific Inc.
6.1.9 Novartis AG
6.1.10 GeneTex Inc.
6.1.11 Novavax Inc.
6.1.12 GigaGen Inc.
6.1.13 Biocon
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security